+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms, 2020-2030

  • ID: 4988881
  • Report
  • January 2020
  • Region: Global
  • 357 Pages
  • Roots Analysis
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 5AM Ventures
  • Calico Labs
  • Evotec
  • Jules Bordet Institute
  • OrbiMed
  • Swedbank Robur
  • MORE

Overview

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. Owing to various reasons, conventional pharmacological interventions have been severely restricted in terms of accessing protein targets of pathological significance. However, researchers engaged in developing bifunctional protein degrader-based interventions claim that this upcoming class of medicinal compounds possess the capability to access the part of the eukaryotic proteome that was previously considered undruggable.

The science behind this innovation revolves around the use of specially designed small molecules that are capable of recruiting the ubiquitin-proteasome system (UPS) to selectively eliminate a target protein, via proteolysis. The applications of this technology in drug discovery are vast. Further, drugs designed/based on this concept are known to demonstrate a remarkable level of selectivity, high potency, oral bioavailability and differentiated pharmacology, when compared to traditional occupancy-based inhibitors. As a result, targeted protein degradation-based therapeutics have generated enthusiasm within the medical science community, thereby, defining a new frontier in the field of medicine. The growing popularity and interest in the therapeutic potential of these molecules is evident across modern scientific literature (500+ related articles on NCBI’s PubMed portal), and from social media chatter (4,000+ tweets posted on the platform, Twitter, over the last three years).

The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Over the years, significant progress has been made towards understanding the physiochemical and biological properties of these bifunctional molecules. In fact, a variety of other chemical entities and molecular glues have been developed for the treatment of a variety of clinical conditions, including acute myeloid leukemia, Alzheimer's disease, breast cancer, myelofibrosis, multiple myeloma, Parkinson's disease, prostate cancer, psoriasis, rheumatoid arthritis, and supranuclear palsy.

R&D efforts in this field are being supported by novel DNA-encoded libraries and other versatile bioinformatics tools, which are enabling efficient hit discovery and characterization of potential therapeutic leads. So far, investments worth over USD 3.5 billion have been made in this emerging field of research by various private and public investors. In addition, technology developers with expertise in targeted protein degradation are known to have been involved in several big licensing deals. It is also worth mentioning that, in the last 4-5 years, there has been a marked rise in the number of new entrants in this market. Interestingly, several big pharma players are also actively evaluating protein degraders. Although there are no approved protein degrader-based drugs/therapy products in the market yet, we can expect targeted protein degradation to become a major therapeutic modality in the coming decade.

Scope of the Report

The ‘Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics, 2020-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade. The focus of this study is on specially designed small molecule degraders, including degronimids, endosome targeting chimeras (ENDTACs), epichaperome inhibitors, hydrophobic tags, immuno-modulatory imide drugs (IMiDs), lysosome targeting chimeras (LYTACs), molecular glues, photochemically targeting chimeras (PHOTACs), proteolysis targeting chimeras (PROTACs), protein homeostatic modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor degraders (SERDs), specific and non-genetic IAP-dependent protein erasers (SNIPERs), and specific bromodomain and extra-terminal motif (BET) inhibitors and deubiquitinase (DUB) inhibitors. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of targeted protein degradation-based therapeutics, providing information on drug/therapy developer(s) (such as year of establishment, company size and location of headquarters), clinical study sponsor(s) and collaborator(s), type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of target protein(s), target enzyme(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of targeted protein degraders.
  • Elaborate profiles of key players that are engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history.
  • Brief tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates.
  • A detailed clinical trial analysis of completed, ongoing and planned studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.
  • An assessment of the relative experience of key opinion leaders (KOLs) within this domain, (shortlisted based on their involvement in various clinical studies), featuring detailed 2X2 matrices (based on the strength and activeness of KOLs), a schematic world map representation (highlighting the geographical locations of eminent scientists/researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).
  • An analysis of the partnerships that have been established in the domain, over the period 2014-Q3 2019, covering research agreements, product/technology licensing agreements, mergers/acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants/awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for novel technologies designed for the development of targeted protein degraders. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2020-2030. The report features likely distribution of the current and forecasted opportunity across [A] type of protein degrader (degronimids, IMiDs, PROTACs, SARDs, SERDs, and specific BET and DUB inhibitors), [B] therapeutic area (inflammatory disorders, neurological disorders, oncological disorders, respiratory disorders, and other therapeutic areas), [C] route of administration (oral, intravenous and others), [D] key contributing technologies and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties associated with the growth of targeted protein degradation market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 5AM Ventures
  • Calico Labs
  • Evotec
  • Jules Bordet Institute
  • OrbiMed
  • Swedbank Robur
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Protein Homeostasis
3.3. Post Translational Protein Modifications
3.4. Ubiquitin and the Ubiquitin Proteasome System (UPS)
3.4.1. Structure and Functions of Ubiquitin
3.4.2. Overview of the UPS
3.4.2.1. Components of the UPS
3.4.2.2. Ubiquitin-based Protein Degradation Pathway
3.5. Therapeutic Applications of the UPS
3.6. Ubiquitin Enzyme Inhibitors
3.6.1. Advantages and Challenges
3.7. Overview of Targeted Protein Degradation
3.7.1. Historical Development of Protein Degraders
3.7.2. Types of Protein Degraders
3.7.2.1. Proteolysis Targeting Chimeras (PROTACs)
3.7.2.2. Other Chimeric Protein Targeting Molecules
3.7.2.2.1. Endosome Targeting Chimeras (ENDTACs)
3.7.2.2.2. Lysosome Targeting Chimeras (LYTACs)
3.7.2.2.3. Photochemically Targeted Chimeras (PHOTACs)
3.7.2.3. Epichaperome Inhibitors
3.7.2.4. Hydrophobic Tags
3.7.2.5. Immuno-modulatory Imide Drugs (IMiDs)
3.7.2.6. Molecular Glues
3.7.2.7. Protein Homeostatic Modulators
3.7.2.8. Selective Hormone Receptor Degraders (SHRDs)
3.7.2.9. Specific and Non-genetic IAP-dependent Protein Erasers (SNIPERs)
3.7.2.10. Specific Bromodomain and Extra-terminal Motif (BET) Inhibitors and Deubiquitinase (DUB) Inhibitors
3.8. Growth Drivers and Roadblocks
3.9. Recent Developments and Upcoming Trends
 
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline
4.2.1. Analysis by Type of Protein Degrader
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Type of Target Protein
4.2.6. Analysis by Type of Target Enzyme
4.2.7. Analysis by Type of Therapy
4.2.8. Analysis by Route of Administration
4.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Research Tools / Key Technology Platforms
4.4. Targeted Protein Degradation-based Therapeutics and Technologies: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Size of Company
4.4.3. Analysis by Type of Protein Degrader
4.4.4. Analysis by Location of Headquarters
4.4.5. Leading Developers: Analysis by Number of Drug Candidates
 
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Developers with Late-stage Clinical Candidates
5.2.1. Radius Health
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Targeted Protein Degradation-based Drug Portfolio
5.2.1.3.1. Elacestrant (RAD1901)
5.2.1.4. Recent Developments and Future Outlook
5.2.2. Celgene
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Targeted Protein Degradation-based Drug Portfolio
5.2.2.3.1. Avadomide (CC-122)
5.2.2.3.2. Iberdomide (CC-220)
5.2.2.4. Recent Developments and Future Outlook
5.2.3. Sanofi Genzyme
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Targeted Protein Degradation-based Drug Portfolio
5.2.3.3.1. SAR439859
5.2.3.4. Recent Developments and Future Outlook
5.3. Developers with Preclinical / Early-stage Clinical Candidates
5.3.1. Arvinas
5.3.2. Captor Therapeutics
5.3.3. Genentech
5.3.4. Kymera Therapeutics
5.3.5. Mission Therapeutics
5.3.6. Progenra
5.3.7. Zenopharm
 
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Clinical Trials
6.3.1. Analysis by Trial Registration Year
6.3.2. Geographical Analysis by Number of Clinical Trials
6.3.3. Geographical Analysis by Enrolled Patient Population
6.3.4. Analysis by Type of Protein Degrader
6.3.5. Analysis by Phase of Development
6.3.6. Analysis by Study Design
6.3.7. Analysis by Type of Sponsor / Collaborator
6.3.8. Most Active Players: Analysis by Number of Registered Trials
6.3.9. Analysis by Trial Focus
6.3.10. Analysis by Therapeutic Area
6.3.11. Analysis by Clinical Endpoints
 
7. KOL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators Involved in Clinical Trials
7.3.1. Analysis by Designation
7.3.2. Analysis by Phase of Development and Type of Protein Degrader
7.3.3. Analysis by Focus Therapeutic Area
7.3.4. Analysis by Type of Organization
7.3.5. Analysis by Location of Organization
7.3.6. Leading Organizations: Analysis by Number of Affiliated Principal Investigators
7.4. Prominent Key Opinion Leaders (KOLs)
7.5. KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)
7.6. Profiles of Most Active KOLs
7.6.1. Profile: KOL A (Barbara Ann Karmanos Cancer Center)
7.6.2. Profile: KOL B (Celgene)
7.6.3. Profile: KOL C (Feinberg School of Medicine, Northwestern University)
7.6.4. Profile: KOL D (Royal Marsden NHS Foundation Trust)
7.6.5. Profile: KOL E (Samus Therapeutics)
7.6.6. Profile: KOL F (Stanford Women Cancer Center)
7.6.7. Profile: KOL G (University of North Carolina at Chapel Hill)
7.6.8. Profile: KOL H (University of Toledo)
 
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Collaborations and Partnerships
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Protein Degrader
8.3.4. Analysis by Technology Platform
8.3.5. Analysis by Therapeutic Area
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Geographical Analysis
8.3.7.1. Most Active Players: Regional Analysis by Number of Partnerships
8.3.7.2. Intercontinental and Intracontinental Agreements
 
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Targeted Protein Degradation-based Therapeutics and Technologies: Recent Funding Instances
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Types of Degraders
9.3.5. Analysis by Number of Funding Instances and Amount Invested across Different Therapeutic Areas
9.3.6. Analysis by Amount Invested across Different Technology Platforms
9.3.7. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
9.3.8. Most Active Investors: Analysis by Participation
9.3.9. Geographical Analysis by Amount Invested
9.4. Concluding Remarks
 
10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Targeted Protein Degradation-based Therapeutics and Technologies: Information on Licensing Deals
10.4. Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2020-2030
10.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader
10.4.1.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2020-2030
10.4.1.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for IMiDs, 2020-2030
10.4.1.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2020-2030
10.4.1.4. Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs, 2020-2030
10.4.1.5. Targeted Protein Degradation-based Therapeutics and Technologies Market for SERDs, 2020-2030
10.4.1.6. Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2020-2030
10.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area
10.4.2.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Inflammatory Disorders, 2020-2030
10.4.2.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, 2020-2030
10.4.2.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2020-2030
10.4.2.4. Targeted Protein Degradation-based Therapeutics and Technologies Market for Respiratory Disorders, 2020-2030
10.4.2.5. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2020-2030
10.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration
10.4.3.1. Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2020-2030
10.4.3.2. Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2020-2030
10.4.3.3. Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, 2020-2030
10.4.4. Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Geography
10.4.4.1. Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2020-2030
10.4.4.2. Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2020-2030
10.4.4.3. Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2020-2030
10.4.5. Targeted Protein Degradation-based Therapeutics and Technologies Market: Share of Key Contributing Technologies, 2020-2030
 
11. EXECUTIVE INSIGHTS
 
12. CONCLUDING REMARKS
12.1. Chapter Overview
12.2. Key Takeaways
 
13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures
Figure 3.1 Important Mechanisms of Protein Surveillance
Figure 3.2 Common Types of Post-translational Modifications
Figure 3.3 Mechanism-based Analogies in Phosphorylation and Ubiquitination
Figure 3.4 Key Differences in Phosphorylation and Ubiquitination
Figure 3.5 Types of Proteins Associated with Ubiquitin
Figure 3.6 Genetic Evolution of the UPS in Eukaryotes
Figure 3.6 Key Components of the UPS
Figure 3.7 Key Steps Involved in Protein Degradation via the Ubiquitin-Proteasome Pathway
Figure 3.8 Different Modes of Ubiquitination
Figure 3.9 Biological Functions of Ubiquitination
Figure 3.10 Disease Development Process in the UPS
Figure 3.11 Key Therapeutic Areas Targeted by UPS Modulating Drug Candidates
Figure 3.12 Key Differences Between Protein Degrader and Protein Inhibitor
Figure 3.13 Historical Evolution of Targeted Protein Degradation
Figure 3.14 Types of Protein Degraders
Figure 3.15 Mechanism of Action of PROTACs
Figure 3.16 Mechanism of Action of ENDTACs
Figure 3.17 Mechanism of Action of LYTACs
Figure 3.18 Mechanism of Action of PHOTACs
Figure 3.19 Mechanism of Action of Epichaperome Inhibitors
Figure 3.20 Mechanism of Action of Hydrophobic Tags
Figure 3.21 Mechanism of Action of IMiDs
Figure 3.22 Mechanism of Action of Molecular Glues
Figure 3.23 Mechanism of Action of Protein Homeostatic Modulators
Figure 3.24 Mechanism of Action of SHRDs
Figure 3.25 Mechanism of Action of SNIPERs
Figure 3.26 Key Growth Drivers and Roadblocks Related to Targeted Protein Degraders
Figure 4.1 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Type of Protein Degrader
Figure 4.2 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Phase of Development
Figure 4.3 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Phase of Development and Type of Protein Degrader
Figure 4.4 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area
Figure 4.5 Popular Indications: Distribution by Number of Drug Candidates
Figure 4.6 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Type of Protein Degrader
Figure 4.7 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Phase of Development
Figure 4.8 Popular Target Enzymes: Distribution by Number of Drug Candidates
Figure 4.9 Popular Target Proteins: Distribution by Number of Drug Candidates
Figure 4.10 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Target Protein and Type of Protein Degrader
Figure 4.11 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Target Protein and Phase of Development
Figure 4.12 Targeted Protein Degradation-based Therapeutics and Technologies: Grid Analysis
Figure 4.13 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Type of Therapy
Figure 4.14 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Route of Administration
Figure 4.15 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Year of Establishment
Figure 4.16 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Location of Headquarters
Figure 4.17 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Size of Company
Figure 4.18 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Type of Protein Degrader
Figure 4.19 Targeted Protein Degradation-based Therapeutics and Technologies: Geographical Distribution of Industry Players by Type of Protein Degrader
Figure 4.20 Leading Developers: Distribution by Number of Drug Candidates
Figure 5.1 Radius Health: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Figure 5.2 Celgene: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Figure 5.3 Sanofi Genzyme: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Figure 6.1. Clinical Trials: Distribution by Trial Status
Figure 6.2 Clinical Trials: Cumulative Distribution by Registration Year, Pre-2012-Q3 2019
Figure 6.3 Clinical Trials: Geographical Distribution of Trials
Figure 6.4 Clinical Trials: Geographical Distribution of Enrolled Patient Population
Figure 6.5 Clinical Trials: Distribution by Trial Phase
Figure 6.6 Clinical Trials: Distribution by Type of Protein Degrader
Figure 6.7 Clinical Trials: Distribution by Type of Protein Degrader and Trial Phase
Figure 6.8 Clinical Trials: Distribution by Therapeutic Area
Figure 6.9 Popular Indications: Distribution by Number of Trials
Figure 6.10 Clinical Trials: Distribution by Popular Indications and Phase of Development
Figure 6.11 Clinical Trials: Distribution by Therapeutic Area, Type of Protein Degrader, Trial Phase and Trial Registration Year
Figure 6.12 Clinical Trials: Distribution by Study Design
Figure 6.13 Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 6.14 Most Active Players: Distribution by Number of Registered Trials
Figure 6.15 Clinical Trials: Benchmarking by Number of Trials across Popular Indications
Figure 6.16 Clinical Trials: Popular Keywords
Figure 6.17 Clinical Trials: Distribution of Clinical Endpoints by Trial Phase
Figure 7.1 KOLs: Geographical Distribution of Principal Investigators
Figure 7.2 KOLs: Distribution by Designation
Figure 7.3 KOLs: Distribution by Phase of Development and Type of Protein Degrader
Figure 7.4 KOLs: Distribution by Therapeutic Area
Figure 7.5 KOLs: Distribution by Type of Organization
Figure 7.6 KOLs: Distribution by Location of Organization
Figure 7.7 Leading Organizations: Distribution by Number of Principal Investigators
Figure 7.8 KOLs: Dot-Plot of Principal Investigators
Figure 7.9 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Figure 7.10 Most Prominent KOLs
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Protein Degrader
Figure 8.5 Partnerships and Collaborations: Year-wise Trend by Type of Protein Degrader
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Protein Degrader and Partnership Model
Figure 8.7 Leading Technology Platforms: Distribution by Number of Partnerships
Figure 8.8 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.9 Partnerships and Collaborations: Distribution by Therapeutic Area and Partnership Model
Figure 8.10 Most Active Players: Distribution by Number of Partnerships
Figure 8.11 Most Active Players: Regional Distribution by Number of Partnerships
Figure 8.12 Partnerships and Collaborations: Regional Distribution (Intercontinental and Intracontinental Agreements)
Figure 9.1 Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2014-Q3 2019
Figure 9.2 Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2014-Q3 2019
Figure 9.3 Funding and Investments: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 9.4 Funding and Investments: Cumulative Amount Invested by Year, 2014-Q3 2019 (USD Million)
Figure 9.5 Funding and Investments: Distribution by Type of Funding
Figure 9.6 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 9.7 Funding and Investments: Summary of Investments, 2014-Q3 2019 (USD Million)
Figure 9.8 Popular Protein Degraders: Distribution by Number of Funding Instances
Figure 9.9 Popular Protein Degraders: Distribution by Amount Invested (USD Million)
Figure 9.10 Funding and Investments: Year-wise Trend of Amount Invested across Different Degraders, 2014-Q3 2019 (USD Million)
Figure 9.11 Popular Technology Platforms: Distribution by Amount Invested (USD Million)
Figure 9.12 Popular Therapeutic Areas: Distribution by Number of Funding Instances
Figure 9.13 Popular Therapeutic Areas: Distribution by Number of Funding Instances across Different Degraders
Figure 9.14 Popular Therapeutic Areas: Distribution by Amount Invested (USD Million)
Figure 9.15 Most Active Players: Distribution by Number of Instances
Figure 9.16 Most Active Players: Distribution by Capital Amount Raised (USD Million)
Figure 9.17 Most Active Investors: Distribution by Number of Instances
Figure 9.18 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Figure 9.19 Funding and Investment Summary
Figure 10.1 Targeted Protein Degradation-based Therapeutics and Technologies: Information on Licensing Deals
Figure 10.2 Targeted Protein Degradation-based Therapeutics and Technologies: Average Value and Volume of Upfront Payments (Units, USD Million)
Figure 10.3 Targeted Protein Degradation-based Therapeutics and Technologies: Average Value and Volume of Milestone Payments (Units, USD Million)
Figure 10.4 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, 2020-2030 (USD Million)
Figure 10.5 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, 2020-2030 (USD Million)
Figure 10.6 Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, 2020-2030 (USD Million)
Figure 10.7 Targeted Protein Degradation-based Therapeutics and Technologies Market for IMiDs, 2020-2030 (USD Million)
Figure 10.8 Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, 2020-2030 (USD Million)
Figure 10.9 Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs, 2020-2030 (USD Million)
Figure 10.10 Targeted Protein Degradation-based Therapeutics and Technologies Market for SERDs, 2020-2030 (USD Million)
Figure 10.11 Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, 2020-2030 (USD Million)
Figure 10.12 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area, 2020-2030 (USD Million)
Figure 10.13 Targeted Protein Degradation-based Therapeutics and Technologies Market for Inflammatory Disorders, 2020-2030 (USD Million)
Figure 10.14 Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, 2020-2030 (USD Million)
Figure 10.15 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, 2020-2030 (USD Million)
Figure 10.16 Targeted Protein Degradation-based Therapeutics and Technologies Market for Respiratory Disorders, 2020-2030 (USD Million)
Figure 10.17 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, 2020-2030 (USD Million)
Figure 10.18 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 10.19 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, 2020-2030 (USD Million)
Figure 10.20 Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, 2020-2030 (USD Million)
Figure 10.21 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, 2020-2030 (USD Million)
Figure 10.22 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Region, 2020-2030 (USD Million)
Figure 10.23 Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, 2020-2030 (USD Million)
Figure 10.24 Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, 2020-2030 (USD Million)
Figure 10.25 Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, 2020-2030 (USD Million)
Figure 10.26 Targeted Protein Degradation-based Therapeutics and Technologies Market for Key Contributing Technologies, 2020-2030 (USD Million)

List of Tables
Table 3.1 Structural Classification of Ubiquitin  
Table 4.1 Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline
Table 4.2 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Phase of Development
Table 4.3 Targeted Protein Degradation-based Therapeutics and Technologies: Information on Target Enzyme, Target Protein, Signaling Pathway, Type of Therapy and Route of Administration
Table 4.4 Targeted Protein Degradation-based Therapeutics and Technologies: Information on Marketed First Generation Protein Degraders
Table 4.5 Targeted Protein Degradation-based Therapeutics and Technologies: Information on Research Tools / Key Technology Platforms
Table 4.6 Targeted Protein Degradation-based Therapeutics and Technologies: Developer Landscape
Table 5.1 Radius Health: Key Highlights
Table 5.2 Drug Profile: Elacestrant (RAD1901)
Table 5.3 Radius Health: Recent Developments and Future Outlook
Table 5.4 Celgene: Key Highlights
Table 5.5 Drug Profile: Avadomide (CC-122)
Table 5.6 Drug Profile: Iberdomide (CC-220)
Table 5.7 Celgene: Recent Developments and Future Outlook
Table 5.8 Sanofi Genzyme: Key Highlights
Table 5.9 Drug profile: SAR439859
Table 5.10 Sanofi Genzyme: Recent Developments and Future Outlook
Table 5.11 Arvinas: Key Highlights
Table 5.12 Captor Therapeutics: Key Highlights
Table 5.13 Genentech: Key Highlights
Table 5.14 Kymera Therapeutics: Key Highlights
Table 5.15 Mission Therapeutics: Key Highlights
Table 5.16 Progenra: Key Highlights
Table 5.17 Zenopharm: Key Highlights
Table 6.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Clinical Trials
Table 6.2 Clinical Trials: Distribution by Registration Year and Type of Protein Degrader
Table 6.3 Clinical Trials: Popular Clinical Endpoints by Phase of Development
Table 7.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Principal Investigators
Table 7.2 KOLs: Roots Analysis Proprietary Scoring System
Table 7.3 Profile: KOL A (Barbara Ann Karmanos Cancer Center)
Table 7.4 Profile: KOL B (Celgene)
Table 7.5 Profile: KOL C (Feinberg School of Medicine, Northwestern University)
Table 7.6 Profile: KOL D (Royal Marsden NHS Foundation Trust)
Table 7.7 Profile: KOL E (Samus Therapeutics)
Table 7.8 Profile: KOL F (Stanford Women Cancer Center)
Table 7.9 Profile: KOL G (University of North Carolina at Chapel Hill)
Table 7.10 Profile: KOL H (University of Toledo)
Table 8.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Partnerships, 2014-Q3 2019
Table 8.2 Most Active Players: Regional Distribution by Number of Partnerships
Table 9.1 Targeted Protein Degradation-based Therapeutics and Technologies: List of Funding Instances, 2014-Q3 2019
Table 9.2 Targeted Protein Degradation-based Therapeutics and Technologies: Summary of Investments
Table 11.1 Xios Therapeutics: Key Highlights
Table 12.1 Targeted Protein Degradation-based Therapeutics and Technologies: Key Takeaways of the Report
Table 13.1 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Type of Protein Degrader
Table 13.2 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Phase of Development
Table 13.3 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Phase of Development and Type of Protein Degrader
Table 13.4 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area
Table 13.5 Popular Indications: Distribution by Number of Drug Candidates
Table 13.6 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Type of Protein Degrader
Table 13.7 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Therapeutic Area and Phase of Development
Table 13.8 Popular Target Enzymes: Distribution by Number of Drug Candidates
Table 13.9 Popular Target Proteins: Distribution by Number of Drug Candidates
Table 13.10 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Target Protein and Type of Protein Degrader
Table 13.11 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Target Protein and Phase of Development
Table 13.12 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Type of Therapy
Table 13.13 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution by Route of Administration
Table 13.14 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Year of Establishment
Table 13.15 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Location of Headquarters
Table 13.16 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Size of Company
Table 13.17 Targeted Protein Degradation-based Therapeutics and Technologies: Distribution of Industry Players by Type of Protein Degrader
Table 13.18 Targeted Protein Degradation-based Therapeutics and Technologies: Geographical Distribution of Industry Players by Type of Protein Degrader
Table 13.19 Leading Developers: Distribution by Number of Drug Candidates
Table 13.21 Radius Health: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Table 13.22 Celgene: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Table 13.23 Sanofi Genzyme: Net Revenues, FY 2014 – Q3 2019 (USD Million)
Table 13.24 Clinical Trials: Distribution by Trial Status
Table 13.25 Clinical Trials: Cumulative Distribution by Registration Year, Pre-2012-Q3 2019
Table 13.26 Clinical Trials: Geographical Distribution of Trials
Table 13.27 Clinical Trials: Geographical Distribution of Enrolled Patient Population
Table 13.28 Clinical Trials: Distribution by Trial Phase
Table 13.29 Clinical Trials: Distribution by Type of Protein Degrader
Table 13.30 Clinical Trials: Distribution by Type of Protein Degrader and Trial Phase
Table 13.31 Clinical Trials: Distribution by Therapeutic Area
Table 13.32 Popular Indications: Distribution by Number of Trials
Table 13.33 Clinical Trials: Distribution by Popular Indications and Phase of Development
Table 13.34 Clinical Trials: Distribution by Study Design
Table 13.35 Clinical Trials: Distribution by Type of Sponsor / Collaborator
Table 13.36 Most Active Players: Distribution by Number of Registered Trials
Table 13.37 Clinical Trials: Benchmarking by Number of Trials across Popular Indications
Table 13.38 Clinical Trials: Distribution of Clinical Endpoints by Trial Phase
Table 13.39 KOLs: Distribution by Designation
Table 13.40 KOLs: Distribution by Phase of Development and Type of Protein Degrader
Table 13.41 KOLs: Distribution by Therapeutic Area
Table 13.42 KOLs: Distribution by Type of Organization
Table 13.43 KOLs: Distribution by Location of Organization
Table 13.44 Leading Organizations: Distribution by Number of Principal Investigators
Table 13.45 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Table 13.46 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-Q3 2019
Table 13.47 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.48 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 13.49 Partnerships and Collaborations: Distribution by Type of Protein Degrader
Table 13.50 Partnerships and Collaborations: Year-wise Trend by Type of Protein Degrader
Table 13.51 Partnerships and Collaborations: Distribution by Type of Protein Degrader and Partnership Model
Table 13.52 Leading Technology Platforms: Distribution by Number of Partnerships
Table 13.53 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 13.54 Partnerships and Collaborations: Distribution by Therapeutic Area and Partnership Model
Table 13.55 Most Active Players: Distribution by Number of Partnerships
Table 13.56 Most Active Players: Regional Distribution by Number of Partnerships
Table 13.57 Partnerships and Collaborations: Regional Distribution (Intercontinental and Intracontinental Agreements)
Table 13.58 Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2014-Q3 2019
Table 13.59 Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2014-Q3 2019
Table 13.60 Funding and Investments: Cumulative Year-wise Trend, 2014-Q3 2019
Table 13.61 Funding and Investments: Cumulative Amount Invested by Year, 2014-Q3 2019 (USD Million)
Table 13.62 Funding and Investments: Distribution by Type of Funding
Table 13.63 Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Table 13.64 Funding and Investments: Summary of Investments, 2014-Q3 2019 (USD Million)
Table 13.65 Popular Protein Degraders: Distribution by Number of Funding Instances
Table 13.66 Popular Protein Degraders: Distribution by Amount Invested (USD Million)
Table 13.67 Funding and Investments: Year-wise Trend of Amount Invested across Different Degraders, 2014-Q3 2019 (USD Million)
Table 13.68 Popular Technology Platforms: Distribution by Amount Invested (USD Million)
Table 13.69 Popular Therapeutic Areas: Distribution by Number of Funding Instances
Table 13.70 Popular Therapeutic Areas: Distribution by Number of Funding Instances across Different Degraders
Table 13.71 Popular Therapeutic Areas: Distribution by Amount Invested (USD Million)
Table 13.72 Most Active Players: Distribution by Number of Instances
Table 13.73 Most Active Players: Distribution by Capital Amount Raised (USD Million)
Table 13.74 Most Active Investors: Distribution by Number of Instances
Table 13.75 Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Table 13.76 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, Conservative Scenario, 2020-2030 (USD Million)
Table 13.77 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, Base Scenario, 2020-2030 (USD Million)
Table 13.78 Overall Targeted Protein Degradation-based Therapeutics and Technologies Market, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.79 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, Conservative Scenario, 2020-2030 (USD Million)
Table 13.80 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, Base Scenario, 2020-2030 (USD Million)
Table 13.81 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Type of Protein Degrader, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.82 Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, Conservative Scenario, 2020-2030 (USD Million)
Table 13.83 Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, Base Scenario, 2020-2030 (USD Million)
Table 13.84 Targeted Protein Degradation-based Therapeutics and Technologies Market for Degronimids, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.85 Targeted Protein Degradation-based Therapeutics and Technologies Market for IMiDs, Conservative Scenario, 2020-2030 (USD Million)
Table 13.86 Targeted Protein Degradation-based Therapeutics and Technologies Market for IMiDs, Base Scenario, 2020-2030 (USD Million)
Table 13.87 Targeted Protein Degradation-based Therapeutics and Technologies Market for IMiDs, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.88 Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, Conservative Scenario, 2020-2030 (USD Million)
Table 13.89 Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, Base Scenario, 2020-2030 (USD Million)
Table 13.90 Targeted Protein Degradation-based Therapeutics and Technologies Market for PROTACs, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.91 Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs, Conservative Scenario, 2020-2030 (USD Million)
Table 13.92 Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs, Base Scenario, 2020-2030 (USD Million)
Table 13.93 Targeted Protein Degradation-based Therapeutics and Technologies Market for SARDs, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.94 Targeted Protein Degradation-based Therapeutics and Technologies Market for SERDs, Conservative Scenario, 2020-2030 (USD Million)
Table 13.95 Targeted Protein Degradation-based Therapeutics and Technologies Market for SERDs, Base Scenario, 2020-2030 (USD Million)
Table 13.96 Targeted Protein Degradation-based Therapeutics and Technologies Market for SERDs, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.97 Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, Conservative Scenario, 2020-2030 (USD Million)
Table 13.98 Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, Base Scenario, 2020-2030 (USD Million)
Table 13.99 Targeted Protein Degradation-based Therapeutics and Technologies Market for Specific BET and DUB Inhibitors, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.100 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area, Conservative Scenario, 2020-2030 (USD Million)
Table 13.101 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area, Base Scenario, 2020-2030 (USD Million)
Table 13.102 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Therapeutic Area, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.103 Targeted Protein Degradation-based Therapeutics and Technologies Market for Inflammatory Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 13.104 Targeted Protein Degradation-based Therapeutics and Technologies Market for Inflammatory Disorders, Base Scenario, 2020-2030 (USD Million)
Table 13.105 Targeted Protein Degradation-based Therapeutics and Technologies Market for Inflammatory Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.106 Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 13.107 Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, Base Scenario, 2020-2030 (USD Million)
Table 13.108 Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurological Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.109 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 13.110 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, Base Scenario, 2020-2030 (USD Million)
Table 13.111 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oncological Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.112 Targeted Protein Degradation-based Therapeutics and Technologies Market for Respiratory Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 13.113 Targeted Protein Degradation-based Therapeutics and Technologies Market for Respiratory Disorders, Base Scenario, 2020-2030 (USD Million)
Table 13.114 Targeted Protein Degradation-based Therapeutics and Technologies Market for Respiratory Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.115 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, Conservative Scenario, 2020-2030 (USD Million)
Table 13.116 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, Base Scenario, 2020-2030 (USD Million)
Table 13.117 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Therapeutic Areas, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.118 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration, Conservative Scenario, 2020-2030 (USD Million)
Table 13.119 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration, Base Scenario, 2020-2030 (USD Million)
Table 13.120 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Route of Administration, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.121 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, Conservative Scenario, 2020-2030 (USD Million)
Table 13.122 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, Base Scenario, 2020-2030 (USD Million)
Table 13.123 Targeted Protein Degradation-based Therapeutics and Technologies Market for Oral Route, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.124 Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, Conservative Scenario, 2020-2030 (USD Million)
Table 13.125 Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, Base Scenario, 2020-2030 (USD Million)
Table 13.126 Targeted Protein Degradation-based Therapeutics and Technologies Market for Intravenous Route, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.127 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, Conservative Scenario, 2020-2030 (USD Million)
Table 13.128 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, Base Scenario, 2020-2030 (USD Million)
Table 13.129 Targeted Protein Degradation-based Therapeutics and Technologies Market for Other Routes, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.130 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Region, Conservative Scenario, 2020-2030 (USD Million)
Table 13.131 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Region, Base Scenario, 2020-2030 (USD Million)
Table 13.132 Targeted Protein Degradation-based Therapeutics and Technologies Market: Distribution by Region, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.133 Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, Conservative Scenario, 2020-2030 (USD Million)
Table 13.134 Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, Base Scenario, 2020-2030 (USD Million)
Table 13.135 Targeted Protein Degradation-based Therapeutics and Technologies Market in North America, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.136 Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, Conservative Scenario, 2020-2030 (USD Million)
Table 13.137 Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, Base Scenario, 2020-2030 (USD Million)
Table 13.138 Targeted Protein Degradation-based Therapeutics and Technologies Market in Europe, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.139 Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, Conservative Scenario, 2020-2030 (USD Million)
Table 13.140 Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, Base Scenario, 2020-2030 (USD Million)
Table 13.141 Targeted Protein Degradation-based Therapeutics and Technologies Market in Asia-Pacific, Optimistic Scenario, 2020-2030 (USD Million)
Table 13.142 Targeted Protein Degradation-based Therapeutics and Technologies Market for Key Contributing Technologies, Conservative Scenario, 2020-2030 (USD Million)
Table 13.143 Targeted Protein Degradation-based Therapeutics and Technologies Market for Key Contributing Technologies, Base Scenario, 2020-2030 (USD Million)
Table 13.144 Targeted Protein Degradation-based Therapeutics and Technologies Market for Key Contributing Technologies, Optimistic Scenario, 2020-2030 (USD Million)

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 5AM Ventures
  • 6 Dimensions Capital
  • AbbVie
  • Abingworth
  • Abramson Cancer Center, University of Pennsylvania
  • Advantech Capital
  • Aisling Capital
  • AJU IB Investment
  • Alexandria Venture Investments
  • Alfred Berg
  • Almac Discovery
  • Altitude Life Science Ventures
  • AM Capital
  • Amgen
  • Amsterdam UMC
  • Amzak Health
  • AnnJi Pharmaceutical
  • ARCH Venture Partners
  • ARENSIA Exploratory Medicine
  • Arpeggio Biosciences
  • Artios Pharma
  • Arvinas
  • Astex Pharmaceuticals
  • AstraZeneca
  • Atlas Venture
  • Aurigene Discovery Technologies
  • Avista Pharma Solutions
  • Barbara Ann Karmanos Cancer Center
  • Bayer
  • Beactica
  • BeiGene
  • Beijing Huarong Sangel Venture Capital
  • Bellco Capital
  • Bessemer Venture Partners
  • Beverly Hills Cancer Center
  • BeyondSpring Pharmaceuticals
  • Biogen
  • BioRap Technologies
  • BioStrategics Consulting
  • BioTheryX
  • Boehringer Ingelheim
  • Borun Investment
  • Boston Biochem
  • Boxer Capital, Tavistock Group
  • Bristol-Myers Squibb
  • BVF Partners
  • C4 Therapeutics
  • Calico
  • Calico Labs
  • Cambridge Breast Cancer Research Unit, University of Cambridge
  • Cambridge Enterprise
  • Cambridge Innovation Capital
  • Cambridge Stem Cell Institute
  • Canaan Partners
  • Cancer Research Technology
  • Capital Pathology
  • Captor Therapeutics
  • Cardinal Partners
  • Carmot Therapeutics
  • Casdin Capital
  • Cedilla Therapeutics
  • Celgene
  • CellCentric
  • Cellzome
  • Center for Molecular and Biomolecular Informatics
  • Centre for Clinical Hematology, Queen Elizabeth Hospital
  • Chemical Computing Group
  • Chengdu Dingjian
  • Children's Hospital of Philadelphia, University of Pennsylvania
  • China Construction Bank
  • Chugai Pharmaceuticals
  • Clarivate Analytics
  • Cobro Ventures
  • Constellation Pharmaceuticals
  • Cormorant Asset Management
  • Cosmo Bio
  • Covance
  • Cowen Private Investments
  • Crede Capital Group
  • CSOP Asset Management
  • Cullgen
  • Cyclofluidic
  • Daegu Gyeongbuk Medical Innovation Foundation
  • Dana-Farber Cancer Institute
  • Deerfield Management
  • Dorian Therapeutics
  • Duke University
  • EG Capital
  • Eisai
  • Elan Science One
  • Eli Lilly
  • Emeriti Bio
  • Epiphron Capital Group
  • Erasmus University Medical Center
  • Eriksam Invest Aktiebolag
  • Eshelman Ventures
  • Eternal Thrive
  • European Molecular Biology Laboratory
  • Everbright Sun Hung Kai
  • Evotec
  • Feinberg School of Medicine, Northwestern University
  • Fidelity Biosciences
  • FIMECS
  • Florida Cancer Specialists & Research Institute
  • FORMA Therapeutics
  • Fosun
  • Fox Chase Cancer Center
  • Franklin Templeton Investments
  • Fred Hutchinson Cancer Research Center
  • G1 Therapeutics
  • Genentech
  • Gilead Sciences
  • Gladiator
  • GlaxoSmithKline
  • GNI Group
  • GV
  • GVK Biosciences
  • H. Lee Moffitt Cancer Center and Research Institute
  • Haisco Pharmaceutical
  • Handelsbanken Fonder
  • Harvard Medical School
  • Hatteras Venture Partners
  • HBM Healthcare Investments
  • HealthCap
  • HealthCare Ventures
  • Hermed Alpha
  • HighLight Capital
  • Hillhouse Capital
  • Hinova Pharmaceuticals
  • HitGen
  • Holy Cross Hospital
  • Honghui Capital
  • Horizon Discovery
  • Horizons Venture
  • Hybrigenics Pharma
  • IDEAYA Biosciences
  • ImmunoLogik
  • Imperial Innovations
  • INIM Pharma
  • Innovate UK
  • Institute of Cancer and Genomic Sciences, University of Birmingham
  • Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
  • InventisBio
  • Invus
  • IP Group
  • Jules Bordet Institute
  • Juno Therapeutics
  • Kronos Bio
  • Kymera Therapeutics
  • Lang Sheng Investment
  • Lilly Ventures
  • Ling Long Private Equity
  • Longwood Fund
  • Lumira Capital
  • Macroceutics
  • Manchester Cancer Research Centre
  • Massachusetts General Hospital
  • Mayo Clinic
  • McGill University
  • MD Anderson Cancer Center
  • MedImmune Ventures
  • Medivir
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Mirae Asset Capital
  • Mission Therapeutics
  • Mitobridge
  • Moonstone Investments
  • Morningside Ventures
  • Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute
  • Mountain Group Partners
  • MRC Cambridge Stem Cell Institute
  • MRL Ventures Fund
  • Mubadala Ventures
  • Nanologica
  • National Cancer Institute
  • National Centre for Research and Development
  • National Institute of Genetics
  • New China Asset Management
  • New Enterprise Associates
  • New Leaf Venture Partners
  • Nextech Invest
  • NIHR CRUK Experimental Cancer Medicine Centre
  • Nordic Cross
  • Novartis
  • Novartis Institutes for BioMedical Research
  • Novartis-Berkeley Center for Proteomics and Chemistry Technologies
  • Nuevolution
  • Nurix Therapeutics
  • Nyenburgh Investment Partners
  • Oerth Bio
  • Ohio State University
  • Olema Pharmaceuticals
  • Omega Funds
  • Oncternal Therapeutics
  • OrbiMed
  • Oriental Securities Capital
  • Oxford Finance
  • PamGene
  • Parexel
  • Pelago Bioscience
  • Perceptive Advisors
  • Pfizer
  • Pin Therapeutics
  • Plexium
  • Polaris Partners
  • PolyProx Therapeutics
  • Profacgen
  • Progenra
  • Promega
  • Prostate Cancer Foundation
  • Proteostasis Therapeutics
  • Providence Investment
  • PTC Therapeutics
  • Pudong Innotek
  • Queen’s University
  • RA Capital Management
  • Radius Health
  • Regeneron Pharmaceuticals
  • Robert-Bosch-Hospital, Stuttgart
  • Roche
  • Rock Springs Capital Management
  • Roswell Park Cancer Institute
  • RT Capital
  • Samus Therapeutics
  • Sanofi Genzyme
  • Sarah Cannon Research Institute
  • Sequoia Capital China
  • Servier
  • Shanghai Broad Resources Investment Management
  • Shanghai Free Trade Zone Equity Fund
  • Shenzhen Sangel Venture Capital
  • Shenzhen Sangel Zhichuang Investment
  • Sirona Capital
  • Sitryx
  • Sofinnova Partners
  • Solar Capital
  • Songhe Capital
  • South Texas Accelerated Research Therapeutics
  • SR One
  • Stanford Women’s Cancer Center
  • Stephenson Cancer Center
  • Suzhou Broad Resources
  • Suzhou Pioneer Pharmaceutical
  • SV Health Investors
  • SV Torch
  • Swedbank Robur
  • Sygnature Discovery
  • Takeda Pharmaceutical
  • Tavistock Life Sciences
  • Tetralogic Pharmaceuticals
  • The Column Group
  • The DMS Group
  • The Institute of Cancer Research
  • The Kraft Group
  • The Michael J. Fox Foundation
  • The Netherlands Cancer Institute
  • The Rockefeller University
  • The Royal Marsden NHS Foundation Trust
  • The Silverstein Foundation for Parkinson’s with GBA
  • Theravance Biopharma
  • Third Rock Ventures
  • Tianyi Hong Kong Development
  • Tokalas
  • Trinitas Capital
  • UbiQ Bio
  • Ubiquigent
  • UCLA Jonsson Comprehensive Cancer Center
  • Ultragenyx
  • Unionen
  • Unity Biotechnology
  • Universitair Ziekenhuis Leuven
  • University Hospital Erlangen
  • University Medical Center Groningen
  • University of California, Berkeley
  • University of Chicago
  • University of Dundee
  • University of Illinois
  • University of Kentucky
  • University of Liverpool
  • University of North Carolina at Chapel Hill
  • University of Oxford
  • University of Strathclyde
  • University of Tennessee Research Foundation
  • University of Toledo
  • University of Washington
  • Vagelos College of Physicians and Surgeons, Columbia University
  • Verastem Oncology
  • Versant Ventures
  • Vertex Pharmaceuticals
  • Vicore Pharma
  • Vida Ventures
  • Vividion Therapeutics
  • Weill Medical College of Cornell University
  • Woodford Patient Capital Trust
  • Wroclaw Research Center EIT+
  • WuXi AppTec
  • Wyeth
  • X-Chem
  • Xios Therapeutics
  • Yale University
  • Yissum
  • Yuanhe Holding
  • Yuansheng Venture Capital
  • Zenopharm
Note: Product cover images may vary from those shown
5 of 4

 

 

Loading
LOADING...

Adroll
adroll